Is Gender Reference Gender-specific? Studies in a Polar Domain

We investigate how gender authorship influences polar, i.e. positive and negative gender reference. Given German-language newspaper texts where the full names of the authors are known and their gender can be inferred from the first names. And given that nouns in the text have gender reference, i.e. are labeled by a gender classifier as female or male denoting nouns. If these nouns carry a polar load, they count towards the gender-specific statistics we are interested in. A polar load is given either via phrase-level sentiment composition, or by a verb-based analysis of the polar role a noun (phrase) plays: is it framed by the verb as a positive or negative actor, or as receiving a positive or negative effect? Also, reported gender-gender relations ({in favor, against}) might be gender-specific. Statistical hypothesis testing is carried out in order to find out whether significant gender-wise correlations exist. We found that, in fact, gender reference is gender-specific: each gender significantly more often focuses on their own gender than the other one and e.g. positive actorship supremacy is claimed (intra-) gender-wise

An Italian Verb Lexicon for Sentiment Inference

Verb-centered sentiment analysis provides a fine-grained perspective on the polar impact a situation has on its participants. It is good for a person to be honored for e.g. some achievement and we know in advance that such an achievement is expected to have positive polarity. Also, there is a positive relation between the honorer and the honoree. We introduce an Italian verb lexicon that specifies the polar relations a verb expresses and the effects and expectations that the roles of the verb bear

Does Concomitant CABG Influence the Outcomes of Post-Myocardial Infarction Ventricular Septal Defect Repair?

Introduction: Ventricular septal defect (VSD) following myocardial infarction (MI) is a relatively infrequent complication with high mortality. Over time, understanding of the pathology and its management has resulted in improved outcomes; however, controversies remain. Objective: We sought to investigate the effect of concomitant coronary artery bypass graft (CABG) on outcomes following post-MI VSD repair. Methods: Electronic search was performed to identify all relevant studies published from 2000 to 2018. After assessment for inclusion and exclusion criteria, 66 studies were selected for the analysis. Data were extracted and pooled for systematic review and meta-analysis. Results: Average age was 68.7 years (95% CI 67.3-70.1) with 57% (95% CI 54-60) males. Coronary angiogram was available preoperatively in 94% (95% CI 92-96) of patients. Single-vessel disease was most common (47%, 95% CI 42-52) with left anterior descending coronary artery the most commonly involved vessel (55%, 95% CI 46-63). Concomitant CABG was performed in 52% (95% CI 46-57) of patients. Of these, infarcted territory was revascularized in 54% (95% CI 23-82). No significant survival difference was observed between those who had concomitant CABG versus those without CABG at 30 days (65%, 95% CI 58-72) vs (60%, 95% CI 47-72), 1 year (59%, 95% CI 50-68) vs (51%, 95% CI 41-61), and 5 years (46%, 95% CI 38-54) vs (39%, 95% CI 27-52) respectively. Discussion: Overall, concomitant CABG did not have a significant effect on survival following VSD repair, therefore, decision on revascularization should be weighed against the risks associated with prolonged cardiopulmonary bypass

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Human Factors Electronic Kneeboard Design Guidelines for Military Tactical Aviation

Great strides have been made in reducing the reams of paper-based materials that pilots were once required to bring into the cockpit. Much of that paper-based information is now available to pilots on electronic devices known as electronic kneeboards (EKBs). The main goal of this paper is to describe a design strategy we are using that integrates interdisciplinary perspectives and engages users in the design process. We describe the use of this design strategy to specify and design EKB applications (i.e., apps) that are uniquely supportive of the work demands faced by tactical pilots. As a result of the work described herein, we will be integrating multiple apps in support of high level goals, i.e., developing super apps. Future work will focus on developing these super apps so that they are responsive to situational changes. Future work additionally includes addressing key challenges associated with navigating within the EKB information space

Human Factors Electronic Kneeboard Design Guidelines for Military Tactical Aviation

Great strides have been made in reducing the reams of paper-based materials that pilots were once required to bring into the cockpit. Much of that paper-based information is now available to pilots on electronic devices known as electronic kneeboards (EKBs). The main goal of this paper is to describe a design strategy we are using that integrates interdisciplinary perspectives and engages users in the design process. We describe the use of this design strategy to specify and design EKB applications (i.e., apps) that are uniquely supportive of the work demands faced by tactical pilots. As a result of the work described herein, we will be integrating multiple apps in support of high level goals, i.e., developing super apps. Future work will focus on developing these super apps so that they are responsive to situational changes. Future work additionally includes addressing key challenges associated with navigating within the EKB information space

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease

Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013–2016 West African EVD outbreak of favipiravir treatment. However, mixed results from these studies hindered regulatory approval of favipiravir for the indication of EVD. This study examined the influence of route of administration, duration of treatment, and treatment schedule of favipiravir in immune competent mouse and guinea pig models using rodent-adapted Zaire ebolavirus (EBOV). A dose of 300 mg/kg/day of favipiravir with an 8-day treatment was found to be fully effective at preventing lethal EVD-like disease in BALB/c mice regardless of route of administration (oral, intraperitoneal, or subcutaneous) or whether it was provided as a once-daily dose or a twice-daily split dose. Preclinical data generated in guinea pigs demonstrates that an 8-day treatment of 300 mg/kg/day of favipiravir reduces mortality following EBOV challenge regardless of route of treatment or duration of treatments for 8, 11, or 15 days. This work supports the future translational development of favipiravir as an EVD therapeutic